Prashant Mehra

1 week ago | capitalbrief.com | Prashant Mehra

Skip to content10:16am on 9 May 2025The news: US aluminium giant Alcoa has named former Brambles CEO Thomas Gorman as its new non-executive chairman. The numbers: Gorman, who has been an independent director on the Alcoa board since May 2021, will take over the role with immediate effect. He comes in after the incumbent, Steve Williams, announced he would step down after eight years in the role.

1 week ago | capitalbrief.com | Prashant Mehra

9:11am on 9 May 2025The news: Medical technology company Avita has lifted first-quarter revenue and reaffirmed its full-year guidance after launching two products in the period. The numbers: Net loss for the three months to March narrowed to US$13.9 million ($21.7 million), from US$18.7 million a year ago. Revenue was up 67% to US$18.5 million, while gross profit margin was 84.7% compared with 86.4% a year ago.

1 week ago | capitalbrief.com | Prashant Mehra

The news: Diversified financial giant Macquarie Group has reported a 5% lift in full-year profit on the back of improved performance in its asset management and financial services businesses. The numbers: Net profit for the year to 31 March was $3.72 billion, ahead of $3.70 billion expected by analysts polled by Visible Alpha. Revenue for the year was up 1.9% to $17.2 billion, and the company will pay a final dividend of $3.90 a share.

1 week ago | capitalbrief.com | Prashant Mehra

The news: The Australian sharemarket is set to open slightly higher following gains on Wall Street, after the US and Britain hammered out a new trade agreement and US President Donald Trump signalled optimism about trade talks with China.

1 week ago | capitalbrief.com | Prashant Mehra

10:07am on 8 May 2025The news: Neuren Pharmaceuticals says US sales of its Retts syndrome treatment drug, Daybue, were higher in the first quarter, with strong potential for future growth. The numbers: Neuren said March quarter sales for Daybue rose 11% in the US to US$84.6 million ($131.6 million), based on reporting by its US partner Acadia Pharmaceuticals. Full-year sales guidance remains at US$380 million to US$405 million.